- Home
- GYRE
as 07-26-2024 4:00pm EST
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 93.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.80 - $30.40 | Next Earning Date: | 08-21-2024 |
| Revenue: | $140,622,000 | Revenue Growth: | 11.23% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Gyre Therapeutics Inc. (GYRE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| USMAN NASSIM | GYRE | Director | Jun 28 '24 | Sell | $12.00 | 3,452 | $41,437.81 | 1,636 | SEC Form 4 |
| USMAN NASSIM | GYRE | Director | May 1 '24 | Sell | $13.86 | 14,900 | $206,514.00 | 6,736 | SEC Form 4 |
| USMAN NASSIM | GYRE | Director | May 1 '24 | Sell | $14.90 | 5,000 | $74,500.00 | 1,736 | SEC Form 4 |
| USMAN NASSIM | GYRE | Director | May 1 '24 | Sell | $15.63 | 100 | $1,563.00 | 1,636 | SEC Form 4 |
| USMAN NASSIM | GYRE | Director | Apr 1 '24 | Sell | $16.15 | 20,000 | $323,000.00 | 1,636 | SEC Form 4 |
| USMAN NASSIM | GYRE | Director | Mar 15 '24 | Sell | $17.26 | 20,000 | $345,200.00 | 1,636 | SEC Form 4 |
Latest Gyre Therapeutics Inc. News
GYRE Breaking Stock News: Dive into GYRE Ticker-Specific Updates for Smart Investing
GlobeNewswire
24 days ago
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Simply Wall St.
a month ago
Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)
GlobeNewswire
a month ago
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
2 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
2 months ago
Share buy-back programme - week 23
Simply Wall St.
2 months ago
Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
Reuters
2 months ago
Japan's service sector mood hits nearly 2-year low in May
Compare GYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GYRE Gyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.